Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study
Open Access
- 16 December 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (24) , e043620
Abstract
Background: The discovery of driver mutations has transformed advanced non–small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)–rearranged patients achieving longest overall survival. However, the risk of cancer therapy–related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second‐generation ALK–tyrosine kinase inhibitors alectinib and brigatinib to the third‐generation tyrosine kinase inhibitor lorlatinib, which offers the longest progression‐free survival. We aimed to compare CTRCVDs risks among patients with lung cancer receiving ALK‐tyrosine kinase inhibitor, assess incidence trends, and identify clinical risk factors associated with ALK‐tyrosine kinase inhibitor‐related CTRCVDs. Methods: This retrospective cohort study of 946 848 adults with lung cancer (2010–2024) using TriNetX compared CTRCVDs risk in ALK‐mutated patients treated with lorlatinib versus brigatinib/alectinib. After excluding ROS1‐mutated cases and 1:1 propensity score matching, 744 patients per group were analyzed. CTRCVDs, defined as myocardial infarction, stroke, arterial embolism, or heart failure, were evaluated with Kaplan–Meier analysis and Cox proportional hazards models over 2 years. Results: Lorlatinib treatment was associated with a significantly increased risk of CTRCVDs (hazard ratio [HR], 3.00 [95% CI, 1.65–5.45]; P P =0.04), atrial fibrillation/flutter history (HR, 2.39 [95% CI, 1.13–5.07]; P =0.002), and lorlatinib use (HR, 2.42 [95% CI, 1.57–3.72]; P <0.001) as independent predictors. Conclusion: These findings underscore the importance of routine cardiovascular monitoring, particularly in older patients and those with atrial arrhythmias.Keywords
This publication has 50 references indexed in Scilit:
- Cardiac Events and Survival in Patients With EGFR-Mutant Non–Small Cell Lung Cancer Treated With OsimertinibJAMA Network Open, 2024
- Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK‐Positive Non‐small Cell Lung CancerClinical Lung Cancer, 2024
- Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?Annals of Oncology, 2024
- Under-reporting of subjective symptoms and its prognostic value: a pooled analysis of 12 cancer clinical trialsESMO Open, 2024
- Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyESMO Open, 2022
- Cardiovascular disease-specific mortality in 270,618 patients with non-small cell lung cancerInternational Journal of Cardiology, 2021
- Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX studyAnnals of Oncology, 2020
- Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare PractitionersAdvances in Therapy, 2020
- Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentClinical Pharmacology & Therapeutics, 2017
- Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patientsCancer, 2013